The effect of Salmeterol on some parameters of pulmonary ventilation in smokers and non- smokers with chronic obstructive pulmonary disease

There are many factors that effect on the lungs capacity and treatment process in chronic obstructive pulmonary disease (COPD). Smoking, as a risk factor, is important in this process. The aim of this study was to evaluate the efficacy of Salmeterol on some parameters of pulmonary ventilation in smokers and non-smokers patients with COPD. This desiccative analytical study was done on 117 patients with respiratory symptoms of COPD who had referred to an internist during 2010-2013 in Sabzevar city, Iran. Data collection methods include observation, clinical symptoms, and respiratory test (spirometry) that was performed by a physician. Before and after Salmeterol inhalation, pulmonary function tests were performed, and pulmonary parameters FEVI, FVC, FEV1% and PEF were measured and recorded. Data were analyzed using paired t test, and independent t test. Of 117 patients 75(64%) were male and 42(36%) were female. The mean age of smokers and non-smokers was 42.36±18.20 and 50.14±18.56, respectively; which was statistically significan (P<0.03). FEV1% was significantly different in COPD patients before and after Salmeterol inhalation (97.44±10.84 and 94.75±10.81, respectively) (P<0.04). In smokers, before Salmeterol inhalation, the mean forced expiratory volume in the first second (FEVI), was lower than non-smokers, but after Salmeterol inhalation, was higher than non- smokers, but not significant. Also, after Salmeterol inhalation, FEVI% was higher in non-smokers compared with smokers. In smokers, COPD onset is 8 years earlier than non-smokers, and Salmeterol inhalation decreases FEVI% in COPD patients.